"FDA approves Dymicron’s study of cervical artificial disc" was originally created and published by Medical Device Network, a ...

Nanoscope’s BLA has been granted rolling review by the FDA, with the first modules already submitted. The completion of the ...

The Food and Drugs Authority (FDA) has officially named Professor Kwabena Frimpong-Manso Opuni as its new Acting Chief Executive Officer, with the appointment taking effect from today, Monday 14th.

Special Report: Imagion Biosystems is on track to start its Phase II clinical trial for HER2 breast cancer and submit an ...

Institute of Human Genetics at Heidelberg University Hospital ongoing EEG biomarker study on 15q13.3 CNVs – – Collaboration aims to uncover novel insights into the brain’s functional architecture in ...

Nanoscope Therapeutics begins rolling submission of BLA to US FDA for gene-agnostic therapy, MCO-010 to treat retinitis pigmentosa: Dallas, Texas Wednesday, July 16, 2025, 14:30 H ...

The Food and Drugs Authority (FDA) has announced the appointment of Professor Kwabena Frimpong-Manso Opuni as its new Acting Chief Executive Officer (CEO), effective Monday, July 14, 2025.

The FDA on the other hand acted promptly against the canteen operator. In its order issued on Wednesday, the FDA said, “The ...

Patients with neuro conditions are asked to consult with their neurologist, above all else, before seeking out therapeutic ...

The FDA granted fast track designation to TRE-515 plus radioligand therapy for treating PSMA-positive metastatic castration-resistant prostate cancer.

President John Mahama has named Professor Kwabena Frimpong-Manso Opuni as Acting Chief Executive Officer of the Food and Drugs Authority (FDA), effective ...